Senior Manager, Scientific Communications & Medical Education

Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity.

Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage development for hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI), including congenital hyperinsulinism (cHI), the most common cause of persistent hypoglycemia in infants and children.